Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines | Zendy

Jordi CodonyServat | Zendy; Santiago Viteri | Zendy; Carles Codony | Zendy; Masaoki Ito | Zendy; J. Bracht | Zendy; Jordi Berenguer | Zendy; Imane Chaib | Zendy; Miguel Ángel MolinaVila | Zendy; Niki Karachaliou | Zendy; Rafael Rosell | Zendy

Open Access

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines

Author(s) -

Jordi CodonyServat,

Santiago Viteri,

Carles Codony,

Masaoki Ito,

J. Bracht,

Jordi Berenguer,

Imane Chaib,

Miguel Ángel MolinaVila,

Niki Karachaliou,

Rafael Rosell

Publication year - 2019

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2019.08.22

Subject(s) - osimertinib , viability assay , cancer research , cell culture , protein kinase b , heat shock protein , lung cancer , hsp90 inhibitor , cell growth , hsp90 , cell , phosphorylation , biology , medicine , chemistry , microbiology and biotechnology , biochemistry , receptor , epidermal growth factor receptor , pathology , genetics , gene , erlotinib

Osimertinib improve therapy for non-small cell lung cancer (NSCLC). However, invariable acquired resistance appears.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research